After a median follow-up of 74 months ( IQR 43-122 ) , overall survival was significantly better with regorafenib than it was with placebo ( hazard ratio 055 , 95 % CI 040-077 , one-sided p = 000016 ; median overall survival 88 months [ 95 % CI 73-98 ] in the regorafenib group vs 63 months [ 48-76 ] in the placebo group ) .